<DOC>
	<DOCNO>NCT00122629</DOCNO>
	<brief_summary>Triple antiviral therapy peg-interferon-alfa/ribavirin+amantadine suggest increase sustain virological response ( SVR ) rate HCV non-responders standard interferon/ribavirin combination . Patients hepatitis C virus infection eligible fail respond single previous 24 week cycle interferon/ribavirin combination therapy . Non-response defined persistent HCV RNA serum last month treatment . This study test efficacy safety pegylated interferon alfa-2b ribavirin amantadine placebo 48 week .</brief_summary>
	<brief_title>Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared Standard Peg-Interferon Alfa-2b/Ribavirin Previous Hepatitis C Virus ( HCV ) Non Responders</brief_title>
	<detailed_description>Triple antiviral therapy peg-interferon-alfa/ribavirin + amantadine suggest increase sustain virological response ( SVR ) rate HCV non-responders standard interferon/ribavirin combination . The aim study determine addition amantadine PEG-IFN/ribavirin enhances SVR . This study double blind , comparative , prospective multicenter , randomize study . Patients recruit 23 hepatology center France . The protocol approve French ethical committee patient provide write informed consent . Eligible subject randomly assign two treatment group equal proportion . The randomization process generate Department Biostatistics , Hospices Civils de Lyon , Lyon , France . Main inclusion criterion : elevate ALT , detectable HCV RNA , Metavir score equal A1F1 equal F3 . Patients receive PEG-IFN 1.5Âµg/kg/week , ribavirin 800-1200mg/day amantadine 200mg/day placebo 48 week . The primary endpoint sustain virological response , define undetectable HCV-RNA 24 week treatment discontinuation ( week 72 ) . Secondary endpoint biochemical response week 72 define ALT normalization ; histological benefit ; tolerance ; virological biochemical response therapy week 12 , 24 48 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Positive antiHCV antibody test Patients respond treatment standard interferon + ribavirin ( HCV RNA+ PCR last month treatment ) Compensated liver disease Neutrophil count equal to1000/mm3 Platelet count equal 100 giga/L Haemoglobin equal 10g/dL Patients undergone posttreatment liver biopsy within year , show METAVIR histological score equal A1F1 , without cirrhosis ( fibrosis score F4 ) ALT N HCV RNA+ screen Coinfection hepatitis B human immunodeficiency virus Any cause liver disease Active drug abuse , active alcohol consumption 40g/day Organ graft Presence hepatocellular carcinoma Cardiovascular , metabolic , renal , haematological , neurological psychiatric disease Patients previous amantadine use Systemic immunosuppressive antiviral treatment last 24 week history interferon and/or ribavirin intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>peginterferon alfa-2b</keyword>
	<keyword>ribavirin</keyword>
	<keyword>Amantadine</keyword>
</DOC>